Welcome to our dedicated page for Biogen news (Ticker: BIIB), a resource for investors and traders seeking the latest updates and insights on Biogen stock.
Biogen Inc. (Nasdaq: BIIB) is a pioneering biotechnology company founded in 1978, dedicated to discovering, developing, and delivering innovative therapies for people living with serious neurological and neurodegenerative diseases. With a robust portfolio of medicines, Biogen is a global leader in the treatment of multiple sclerosis (MS) and has introduced the first and only approved treatment for spinal muscular atrophy (SMA). The company is also at the forefront of research for Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS).
Headquartered in Cambridge, Massachusetts, Biogen operates worldwide with research facilities in Zug, Switzerland, and state-of-the-art manufacturing plants in North Carolina and Denmark. The company employs approximately 7,000 people globally, emphasizing a collaborative and inclusive work environment.
Biogen's significant achievements include the development of revolutionary MS treatments such as Avonex, Plegridy, Tysabri, Tecfidera, and Vumerity. The company also markets Spinraza for SMA and Leqembi for Alzheimer’s disease, in collaboration with partners like Ionis and Eisai respectively. Biogen continues to expand its pipeline with promising candidates currently in various stages of clinical trials.
Recent developments have seen Biogen and Eisai submit a Supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for monthly maintenance dosing of Leqembi, aimed at treating Alzheimer's disease in its early stages. Furthermore, Biogen published its 2023 Corporate Responsibility Report, highlighting its commitment to sustainable practices and social responsibility across four key pillars.
In addition to its core operations, Biogen collaborates with companies like Delta Flight Products to improve travel experiences for passengers with reduced mobility. This initiative reflects Biogen’s broader mission to enhance the quality of life for individuals facing debilitating conditions.
Biogen's financial health is robust, with strategic mergers and acquisitions like the recent purchase of Human Immunology Biosciences for $1.15 billion, aiming to bolster its immunology pipeline. The company’s comprehensive approach to business involves balancing bold scientific endeavors with prudent financial management to ensure long-term growth and shareholder value.
For more information about Biogen's latest news and updates, visit www.biogen.com.
The FDA has granted accelerated approval for QALSODY (tofersen), a treatment for amyotrophic lateral sclerosis (ALS) in adults with a mutation in the SOD1 gene. This approval is based on a reduction of neurofilament, a biomarker for neurodegeneration, in patients. There are approximately 330 individuals in the U.S. living with this rare genetic form of ALS. The ongoing Phase 3 ATLAS study will serve as a confirmatory trial to assess clinical benefits. While the treatment is groundbreaking, there are warnings about serious neurological events associated with its use. Common adverse reactions include pain, fatigue, and muscle pain. QALSODY represents a significant advancement in ALS therapy, being the first approved treatment targeting a genetic cause.
Biogen has announced the appointment of Adam Keeney, Ph.D., as Executive Vice President and Head of Corporate Development, effective April 17, 2023. Dr. Keeney is set to join the Executive Committee and will report to Christopher A. Viehbacher, the company's President and CEO. With over 20 years in biopharmaceutical strategy and business development, Dr. Keeney previously served as CEO of NodThera and held significant roles at Sanofi and Johnson & Johnson. His appointment comes as Biogen aims for sustainable growth and strategic external collaborations.
Eisai and Biogen announced the publication of detailed analyses from the Phase IIb study of lecanemab, focusing on mild cognitive impairment and early Alzheimer's disease. The peer-reviewed journals highlighted biomarker, cognitive, and clinical effects, consistency of results across measures, and the ARIA profile. Study 201 involved 856 patients and revealed a significant reduction in clinical decline. The treatment demonstrated a dose-dependent reduction in brain amyloid accumulation and favorable safety profiles. Additionally, the Phase 3 Clarity AD study results may confirm clinical benefits, as lecanemab remains under Priority Review by the FDA.
FAQ
What is the current stock price of Biogen (BIIB)?
What is the market cap of Biogen (BIIB)?
What does Biogen Inc. specialize in?
Where is Biogen headquartered?
What are some of Biogen's key products?
How many employees does Biogen have?
What recent acquisitions has Biogen made?
What are Biogen’s latest research initiatives?
How is Biogen improving travel for people with mobility issues?
What is Biogen’s approach to corporate responsibility?
What is Leqembi and what is its significance?
Where can I find more information about Biogen?
